Exports of Chinese bulk drugs will continue maintain rapid growth in 2012

In 2011, exports of Chinese west bulk drugs were 4.98 million tons with an increase of 23.39%. The total exports were $ 20.3 billion by an increase of 26.19%. The average export price was $ 4.07 / kg with an increase of 2.27%. The export volume and export value of bulk drugs both have more than 23% growth. There was a slight increase in average export price. It can be seen that in 2011 exports market of Chinese bulk drugs show a strong recovery trend.

In 2011, the top ten markets of China's API exports are identical to 2010.But India has replaced the U.S. as the largest export destination country for Chinese API. 2011 China's API exports of the top ten markets are compared to a substantial increase, but the six-market average export price fell, reflecting the major markets, price competition remains intense.

In 2011, there were a total of 8563 pharmaceutical raw materials suppliers in exporting drug products. Among the companies whose exports ranked in the top ten, 80% of manufacturers indicating the production of more advantages than the foreign trade enterprises. It is the leader of the exports of bulk drugs. The export volume of the top ten companies have a more substantial increase, an increase of 80% of the enterprises in more than 20%, reflecting the good operating condition of the leading companies. But 40% of the average export price dropped a reflection of the leading enterprises face greater competitive pressures.

From the current situation, in 2012 China's exports of bulk drugs will show the following trends: the export of bulk drugs will continue to maintain rapid growth. The global pharmaceutical market grew 5% to 7%, reaching $ 880 billion in 2011. The global pharmaceutical market will be an increase of 4 percent to 7 percent compound annual growth rate. Therefore, the demand of the international market for the drug substance is stable growth.

In recent years, while production costs on the rise, but the enterprise is more focused on Revamp, self-digest, export price increases is limited, so the prices of bulk drugs in China is still quite competitive. Plus factors of Chinese enterprises in the high-end quality certification, the development of maturity patent bulk drugs, following the efforts of the international federation of pharmaceutical. The production outsourcing and multinational pharmaceutical production are transferred to China. China's API exports remained stable high-speed development. It is expected in 2012, chia seed will maintain a growth rate of 20%.

Export growth will be mainly reflected in the increase of the number. The price will be flat or increase slightly. The rigid demand of pharmaceutical market determines the demand for bulk drugs number. China's huge production capacity needs to be digested in the international market which will promote China's exports of bulk drugs to maintain a steady growth in the number. But with the situation of production surplus in Chinese bulk raw material drug, competition fierce, slow international economic recovery and currency devaluation in a number of nations, Chinese bulk drugs’ export price is difficult to rise. But cost increase in all aspects also makes the export price without downstream space. Therefore, prices of pharmaceutical raw materials are likely to remain stable or rise slightly.
 Source:http://www.cospcn.com